D
David Lavie
Researcher at Weizmann Institute of Science
Publications - 171
Citations - 3772
David Lavie is an academic researcher from Weizmann Institute of Science. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 31, co-authored 144 publications receiving 3597 citations. Previous affiliations of David Lavie include New York University & Israel Institute for Biological Research.
Papers
More filters
Journal ArticleDOI
Therapeutic agents with dramatic antiretroviral activity and little toxicity at effective doses: aromatic polycyclic diones hypericin and pseudohypericin.
TL;DR: Observations to date suggest that pseudohypericin and hypericin could become therapeutic tools against retroviral-induced diseases such as acquired immunodeficiency syndrome (AIDS) and lack of toxicity at therapeutic doses extends to humans.
Journal ArticleDOI
Studies of the mechanisms of action of the antiretroviral agents hypericin and pseudohypericin.
Gad Lavie,Fred T. Valentine,Brandi Levin,Yehuda Mazur,Gloria Gallo,David Lavie,David B. Weiner,Daniel Meruelo +7 more
TL;DR: Accumulating data from the laboratories suggest that these compounds inhibit retroviruses by unconventional mechanisms and that the potential therapeutic value of hypericin and pseudohypericin should be explored in diseases such as AIDS.
Journal ArticleDOI
The chemical and biological properties of hypericin--a compound with a broad spectrum of biological activities.
Journal ArticleDOI
Constituents of Withania somnifera Dun. III. The Side Chain of Withaferin A*,1
Journal ArticleDOI
Constituents of Withania somnifera Dun—XIII
TL;DR: Withania somnifera Dun (Solanaceae) growing in the southern coastal plane of Israel constitutes a new chemotype and is designated as chemotype III as mentioned in this paper, and the following structures have been assigned to seven of the above compounds: Withanolide G, 20α,27dihydroxy-1-oxo-20R,22R-witha-2,5,8(14),24-tetraenolide (2,2,14)